These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8326383)

  • 1. Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer.
    Peltier P; Curtet C; Chatal JF; Le Doussal JM; Daniel G; Aillet G; Gruaz-Guyon A; Barbet J; Delaage M
    J Nucl Med; 1993 Aug; 34(8):1267-73. PubMed ID: 8326383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
    Barbet J; Peltier P; Bardet S; Vuillez JP; Bachelot I; Denet S; Olivier P; Leccia F; Corcuff B; Huglo D; Proye C; Rouvier E; Meyer P; Chatal JF
    J Nucl Med; 1998 Jul; 39(7):1172-8. PubMed ID: 9669389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer.
    Vuillez JP; Moro D; Brichon PY; Rouvier E; Brambilla E; Barbet J; Peltier P; Meyer P; Sarrazin R; Brambilla C
    J Nucl Med; 1997 Apr; 38(4):507-11. PubMed ID: 9098191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.
    Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thédrez P; Fiche M; Gautherot E; Barbet J; Chatal JF
    J Nucl Med; 1998 Sep; 39(9):1608-13. PubMed ID: 9744353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoscintigraphy using 111In-labeled F(ab')2 fragments of anticarcinoembryonic antigen monoclonal antibody for detecting recurrences of medullary thyroid carcinoma.
    Vuillez JP; Peltier P; Caravel JP; Chetanneau A; Saccavini JC; Chatal JF
    J Clin Endocrinol Metab; 1992 Jan; 74(1):157-63. PubMed ID: 1727816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate.
    Boerman OC; Kranenborg MH; Oosterwijk E; Griffiths GL; McBride WJ; Oyen WJ; de Weijert M; Oosterwijk-Wakka J; Hansen HJ; Corstens FH
    Cancer Res; 1999 Sep; 59(17):4400-5. PubMed ID: 10485489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer.
    Bardiès M; Bardet S; Faivre-Chauvet A; Peltier P; Douillard JY; Mahé M; Fiche M; Lisbona A; Giacalone F; Meyer P; Gautherot E; Rouvier E; Barbet J; Chatal JF
    J Nucl Med; 1996 Nov; 37(11):1853-9. PubMed ID: 8917192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful surgical removal of occult metastases of medullary thyroid carcinoma recurrences with the help of immunoscintigraphy and radioimmunoguided surgery.
    de Labriolle-Vaylet C; Cattan P; Sarfati E; Wioland M; Billotey C; Brochériou C; Rouvier E; de Roquancourt A; Rostène W; Askienazy S; Barbet J; Milhaud G; Gruaz-Guyon A
    Clin Cancer Res; 2000 Feb; 6(2):363-71. PubMed ID: 10690512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response.
    Le Doussal JM; Chetanneau A; Gruaz-Guyon A; Martin M; Gautherot E; Lehur PA; Chatal JF; Delaage M; Barbet J
    J Nucl Med; 1993 Oct; 34(10):1662-71. PubMed ID: 8410279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
    van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging of medullary carcinoma of the thyroid using 111In-labelled anti-CEA monoclonal antibody fragments.
    O'Byrne KJ; Hamilton D; Robinson I; Sweeney E; Freyne PJ; Cullen MJ
    Nucl Med Commun; 1992 Mar; 13(3):142-8. PubMed ID: 1557212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
    Kraeber-Bodéré F; Rousseau C; Bodet-Milin C; Ferrer L; Faivre-Chauvet A; Campion L; Vuillez JP; Devillers A; Chang CH; Goldenberg DM; Chatal JF; Barbet J
    J Nucl Med; 2006 Feb; 47(2):247-55. PubMed ID: 16455630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.
    Kraeber-Bodéré F; Faibre-Chauvet A; Saï-Maurel C; Gautherot E; Fiche M; Campion L; Le Boterff J; Barbet J; Chatal JF; Thédrez P
    J Nucl Med; 1999 Jan; 40(1):198-204. PubMed ID: 9935077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoscintigraphy in medullary thyroid cancer using an 123I- or 111In-labelled monoclonal anti-CEA antibody fragment.
    Reiners C; Eilles C; Spiegel W; Becker W; Börner W
    Nuklearmedizin; 1986 Dec; 25(6):227-31. PubMed ID: 3808964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter clinical trials of monoclonal antibody B72.3-GYK-DTPA 111In (111In-CYT-103; OncoScint CR103) in patients with colorectal carcinoma.
    Abdel-Nabi HH; Doerr RJ
    Targeted Diagn Ther; 1992; 6():73-88. PubMed ID: 1576351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.
    Bodet-Milin C; Faivre-Chauvet A; Carlier T; Rauscher A; Bourgeois M; Cerato E; Rohmer V; Couturier O; Drui D; Goldenberg DM; Sharkey RM; Barbet J; Kraeber-Bodere F
    J Nucl Med; 2016 Oct; 57(10):1505-1511. PubMed ID: 27230928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of different scintigraphic techniques to the management of medullary thyroid carcinoma.
    Sandrock D; Blossey HC; Steinroeder M; Munz DL
    Henry Ford Hosp Med J; 1989; 37(3-4):173-4. PubMed ID: 2576957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunoimaging of non-small cell lung cancer with 111In- and 99mTc-labeled monoclonal anti-CEA-antibodies.
    Kairemo KJ; Aronen HJ; Liewendahl K; Paavonen T; Heikkonen JJ; Virkkunen P; Mäki-Hokkonen H; Karonen SL; Brownell AL; Mäntylä MJ
    Acta Oncol; 1993; 32(7-8):771-8. PubMed ID: 8305225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 3-step pretargeting strategy to image infection.
    Boerman OC; van Eerd J; Oyen WJ; Corstens FH
    J Nucl Med; 2001 Sep; 42(9):1405-11. PubMed ID: 11535733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioimmunoguided surgery in colorectal cancer: a 6-year experience with four different technical solutions.
    Renda A; Iovino F; Capasso L; Ricciardelli L; Tammaro V; Acampa W
    Semin Surg Oncol; 1998 Dec; 15(4):226-30. PubMed ID: 9829377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.